Vulnerable
发表于 2025-3-23 13:33:23
Radiotherapy for Advanced Prostate Cancer,ic grading systems . Prostate cancer is no exception, and accurate risk stratification is paramount to appropriately guide therapy for men with prostate cancer. Traditionally, the treatment of localized or non-metastatic malignancies includes radical local therapy with either radiotherapy or surg
Irritate
发表于 2025-3-23 15:32:48
Optimizing Perioperative Treatment for Kidney Cancer,icians can risk-stratify surgical candidates, make recommendations on targeting vulnerabilities and deficits identified in preoperative assessment, and summarize best practices regarding surgical considerations, postoperative care, and follow-up. In this chapter, we review traditional and commonly u
Antarctic
发表于 2025-3-23 21:05:54
Surgical Treatment for Metastatic Kidney Cancer,atic renal cell carcinoma. The role of cytoreductive nephrectomy and metastasectomy for patients with metastatic disease has evolved accordingly. Historically, level 1 evidence supported the use of cytoreductive nephrectomy in patients treated with interferon. While retrospective studies suggest cyt
联合
发表于 2025-3-23 23:54:08
http://reply.papertrans.cn/95/9444/944307/944307_14.png
因无茶而冷淡
发表于 2025-3-24 02:55:18
http://reply.papertrans.cn/95/9444/944307/944307_15.png
极小量
发表于 2025-3-24 09:10:01
Immunotherapy,eckpoint inhibitors (ICIs) have been approved by the US FDA, adding more options for RCC therapies. Recent clinical trials have shown the potency of ICIs, including anti-PD-1 and anti-CTLA-4 antibodies, as combination and monotherapy in both metastatic and local RCC. However, there is a continued ne
lacrimal-gland
发表于 2025-3-24 10:47:59
Evolving Treatment in Non-muscle-Invasive Bladder Cancer,g many other aspects. Historically, NMIBC has been treated with surgical resection and intravesical BCG. More recently, many other forms of intravesical therapy including non-BCG immunotherapy, chemotherapy, gene therapy, viral therapy, and others, have been studied to treat patients with NMIBC. Pri
Tdd526
发表于 2025-3-24 17:08:36
Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer,sed chemotherapy prior to surgical resection to address occult disseminated disease reduces risk of recurrence and is the current standard of care for MIBC, supported by level I evidence. While adjuvant chemotherapy could theoretically offer similar benefit, postoperative cisplatin-based chemotherap
Monocle
发表于 2025-3-24 21:47:17
Bladder-Sparing Approaches to Treatment of Muscle-Invasive Bladder Cancer,ble for consideration based on certain selection criteria. This chapter describes the clinical entity of MIBC, discusses the selection criteria utilized for evaluating candidacy for SBP, and addresses a multitude of bladder-sparing approaches that have been utilized both historically and in current
种类
发表于 2025-3-25 00:34:11
Treatment of Metastatic Bladder Cancer,ular biology and the tumor microenvironment of bladder cancer has unlocked new opportunities for treatment. Immune checkpoint blockade with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) antibodies has demonstrated durable responses in a subset of patients in the first- and